CLIPPERS is a rare inflammatory disorder of the central nervous system. The full name, Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids, describes the condition in clinical shorthand: immune cells cluster around tiny blood vessels in the brainstem, causing inflammation that shows up on MRI scans and typically improves with steroid treatment. First identified in 2010, CLIPPERS remains poorly understood, with no known cause and no specific blood test to confirm it.
What Happens in the Brain
CLIPPERS centers on a part of the brainstem called the pons, a relay station that helps coordinate balance, eye movement, facial sensation, and basic motor functions. In people with CLIPPERS, a type of white blood cell accumulates around the small blood vessels in this region, triggering chronic inflammation. The immune activity can spread from the pons into neighboring structures like the cerebellum (which controls coordination) and other parts of the brainstem.
The underlying trigger is unknown. Some researchers have proposed that CLIPPERS may fall within a broader family of disorders involving overactive immune cells, including both lymphocytes and macrophages. There is no established genetic link, and it does not appear to be infectious. It is, for now, classified as an inflammatory condition of unknown origin.
Symptoms and How They Develop
Because CLIPPERS targets the brainstem and cerebellum, its symptoms reflect damage to those areas. The clinical presentation is variable, but symptoms tend to be subacute, meaning they build over days to weeks rather than striking suddenly. They are also progressive and episodic, with periods of worsening followed by partial improvement.
Common symptoms include:
- Gait instability and poor coordination (ataxia), often making walking difficult
- Double vision (diplopia) from disrupted eye movement control
- Facial numbness or tingling due to inflammation near cranial nerves
- Slurred speech and difficulty swallowing
- Dizziness and vertigo
Some patients also experience cognitive changes or weakness in the limbs, particularly the legs. In one documented case, a significantly severe weakness in the lower limbs persisted even after treatment, illustrating that while CLIPPERS responds to therapy, recovery is not always complete.
How CLIPPERS Is Diagnosed
There is no single lab test for CLIPPERS. It is a diagnosis of exclusion, meaning doctors must first rule out other conditions that look similar before arriving at this label. The process relies heavily on MRI findings and the patient’s response to steroids.
The hallmark sign on MRI is a distinctive “peppering” pattern: multiple tiny, dot-like and curvilinear lesions that light up with contrast dye, concentrated in the pons and spreading into the cerebellum and brainstem. This pattern is striking enough that experienced neurologists can recognize it, but it is not unique to CLIPPERS. Several serious conditions can mimic this appearance early on.
A study following 42 patients who initially met CLIPPERS criteria found that 13 of them, nearly one in three, turned out to have a different diagnosis. The most common mimics were central nervous system lymphomas (7 cases), a form of brain blood vessel inflammation called primary central nervous system angiitis (4 cases), and autoimmune disorders targeting brain tissue (2 cases). Certain red flags on imaging can help distinguish these mimics: ring-shaped lesions with swelling suggest lymphoma, while narrowed arteries on imaging point toward blood vessel inflammation. Because some of these conditions are life-threatening if missed, careful follow-up and sometimes brain biopsy are part of the diagnostic workup.
Treatment With Steroids
The defining feature of CLIPPERS is its responsiveness to corticosteroids. Both the neurological symptoms and the MRI abnormalities typically improve with high-dose steroid treatment. Acute episodes are usually treated with a short course of high-dose intravenous steroids over three days, followed by a transition to oral steroids that are gradually reduced over weeks to months.
The challenge is what happens when the steroid dose drops. Attempts to taper below a relatively low daily dose often trigger a return of symptoms or new inflammation visible on MRI. The overall relapse rate across published cases is roughly 59%, and relapses are more common in patients who received shorter courses of steroid therapy. This creates a difficult balancing act: steroids work, but staying on them long-term carries its own risks, including bone thinning, weight gain, high blood sugar, and immune suppression.
Long-Term Management
Because most patients cannot safely stay on steroids indefinitely, doctors often add a second medication intended to control the immune system while allowing the steroid dose to come down. The most commonly used options include mycophenolate, methotrexate, and azathioprine, all of which suppress immune activity through different mechanisms.
The results with these medications have been mixed. A single-center case series found that about half of patients on each of these drugs experienced treatment failure, meaning their symptoms returned or their MRI worsened despite the added medication. One patient treated with rituximab, a drug that depletes a specific type of immune cell, remained stable for at least a year. Newer agents are being explored, but no steroid-sparing therapy has yet proven consistently effective across patients.
This means that many people with CLIPPERS end up on some combination of low-dose steroids plus an additional immunosuppressant, adjusted over time based on how their symptoms and MRI scans behave. Treatment is ongoing and individualized.
What to Expect Over Time
CLIPPERS is a chronic condition. While steroid therapy is highly effective at reducing inflammation, remission of symptoms is often incomplete. Some patients recover well between flares and maintain good function for years on maintenance therapy. Others accumulate disability over time, particularly weakness in the legs, coordination problems, or persistent balance issues.
The high risk of relapse during steroid reduction is the central challenge of living with CLIPPERS. Each flare risks additional damage to brainstem tissue, and the medications used to prevent flares require regular monitoring for side effects. Because the condition is rare, most neurologists will have seen very few cases, and patients are often managed at academic medical centers with expertise in neuroimmunology.
The diagnosis itself also requires vigilance. Because CLIPPERS mimics can include lymphoma and other serious diseases, doctors typically continue to monitor MRI scans over time to make sure the original diagnosis holds. If the pattern of disease changes or stops responding to steroids as expected, the diagnosis may need to be reconsidered.